Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.82 USD
-0.02 (-2.44%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $0.81 -0.01 (-0.67%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.82 USD
-0.02 (-2.44%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $0.81 -0.01 (-0.67%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Seres Therapeutics (MCRB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Seres Therapeutics (MCRB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -34.55% and 0.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 0% and 126.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
by Zacks Equity Research
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
by Zacks Equity Research
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -3.23% and 13.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -29.27% and 19.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.
Analysts Estimate Seres Therapeutics (MCRB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -18.18% and 7.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?